The Impact of Histone Post-translational Modifications in Neurodegenerative Diseases

Overview

Journal Biochim Biophys Acta Mol Basis Dis

Publisher Elsevier

Specialties Biochemistry
Biophysics
Genetics
Molecular Biology

Date 2018 Oct 24

PMID 30352259

Citations 24

Authors

Samantha N Cobos

Seth A Bennett

Mariana P Torrente

Affiliations

Soon will be listed here.

Abstract

Every year, neurodegenerative disorders take more than 5000 lives in the US alone. Cures have not yet been found for many of the multitude of neuropathies. The majority of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and Parkinson's disease (PD) cases have no known genetic basis. Thus, it is evident that contemporary genetic approaches have failed to explain the etiology or etiologies of ALS/FTD and PD. Recent investigations have explored the potential role of epigenetic mechanisms in disease development. Epigenetics comprises heritable changes in gene utilization that are not derived from changes in the genome. A main epigenetic mechanism involves the post-translational modification of histones. Increased knowledge of the epigenomic landscape of neurodegenerative diseases would not only further our understanding of the disease pathologies, but also lead to the development of treatments able to halt their progress. Here, we review recent advances on the association of histone post-translational modifications with ALS, FTD, PD and several ataxias.

Citing Articles

Exfoliation syndrome genetics in the era of post-GWAS.

Elsayed O, Cai J, Liu Y Vision Res. 2024; 226:108518.

PMID: 39549468 PMC: 11624108. DOI: 10.1016/j.visres.2024.108518.

Histone post-translational modification and heterochromatin alterations in neurodegeneration: revealing novel disease pathways and potential therapeutics.

Fisher R, Torrente M Front Mol Neurosci. 2024; 17:1456052.

PMID: 39346681 PMC: 11427407. DOI: 10.3389/fnmol.2024.1456052.

From Environment to Gene Expression: Epigenetic Methylations and One-Carbon Metabolism in Amyotrophic Lateral Sclerosis.

Hernan-Godoy M, Rouaux C Cells. 2024; 13(11.

PMID: 38891099 PMC: 11171807. DOI: 10.3390/cells13110967.

Valproic Acid Treatment after Traumatic Brain Injury in Mice Alleviates Neuronal Death and Inflammation in Association with Increased Plasma Lysophosphatidylcholines.

Hummel R, Dorochow E, Zander S, Ritter K, Hahnefeld L, Gurke R Cells. 2024; 13(9.

PMID: 38727269 PMC: 11083124. DOI: 10.3390/cells13090734.

Tsitkov S, Valentine K, Kozareva V, Donde A, Frank A, Lei S Nat Commun. 2024; 15(1):3606.

PMID: 38697975 PMC: 11066062. DOI: 10.1038/s41467-024-47758-8.

References

Gilks W, Abou-Sleiman P, Gandhi S, Jain S, Singleton A, Lees A . A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet. 2005; 365(9457):415-6. DOI: 10.1016/S0140-6736(05)17830-1. View

Della Nave R, Ginestroni A, Giannelli M, Tessa C, Salvatore E, Salvi F . Brain structural damage in Friedreich's ataxia. J Neurol Neurosurg Psychiatry. 2007; 79(1):82-5. DOI: 10.1136/jnnp.2007.124297. View

Polymeropoulos M, Lavedan C, Leroy E, Ide S, Dehejia A, Dutra A . Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276(5321):2045-7. DOI: 10.1126/science.276.5321.2045. View

Chan P, Torres R, Yandim C, Law P, Khadayate S, Mauri M . Heterochromatinization induced by GAA-repeat hyperexpansion in Friedreich's ataxia can be reduced upon HDAC inhibition by vitamin B3. Hum Mol Genet. 2013; 22(13):2662-75. DOI: 10.1093/hmg/ddt115. View

Elgin S . Heterochromatin and gene regulation in Drosophila. Curr Opin Genet Dev. 1996; 6(2):193-202. DOI: 10.1016/s0959-437x(96)80050-5. View

Liu-Yesucevitz L, Lin A, Ebata A, Boon J, Reid W, Xu Y . ALS-linked mutations enlarge TDP-43-enriched neuronal RNA granules in the dendritic arbor. J Neurosci. 2014; 34(12):4167-74. PMC: 3960463. DOI: 10.1523/JNEUROSCI.2350-13.2014. View

Hely M, Morris J, Reid W, Trafficante R . Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord. 2004; 20(2):190-9. DOI: 10.1002/mds.20324. View

Ayrapetov M, Gursoy-Yuzugullu O, Xu C, Xu Y, Price B . DNA double-strand breaks promote methylation of histone H3 on lysine 9 and transient formation of repressive chromatin. Proc Natl Acad Sci U S A. 2014; 111(25):9169-74. PMC: 4078803. DOI: 10.1073/pnas.1403565111. View

Renton A, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs J . A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011; 72(2):257-68. PMC: 3200438. DOI: 10.1016/j.neuron.2011.09.010. View

10.

Tsai C, Kao H, Mitzutani A, Banayo E, Rajan H, McKeown M . Ataxin 1, a SCA1 neurodegenerative disorder protein, is functionally linked to the silencing mediator of retinoid and thyroid hormone receptors. Proc Natl Acad Sci U S A. 2004; 101(12):4047-52. PMC: 384693. DOI: 10.1073/pnas.0400615101. View

11.

Cedar H, Bergman Y . Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet. 2009; 10(5):295-304. DOI: 10.1038/nrg2540. View

12.

Nicholas A, Lubin F, Hallett P, Vattem P, Ravenscroft P, Bezard E . Striatal histone modifications in models of levodopa-induced dyskinesia. J Neurochem. 2008; 106(1):486-94. DOI: 10.1111/j.1471-4159.2008.05417.x. View

13.

Fox S . Non-dopaminergic treatments for motor control in Parkinson's disease. Drugs. 2013; 73(13):1405-15. DOI: 10.1007/s40265-013-0105-4. View

14.

Li Y, Lu Y, Polak U, Lin K, Shen J, Farmer J . Expanded GAA repeats impede transcription elongation through the FXN gene and induce transcriptional silencing that is restricted to the FXN locus. Hum Mol Genet. 2015; 24(24):6932-43. PMC: 4654050. DOI: 10.1093/hmg/ddv397. View

15.

Luger K, Richmond T . The histone tails of the nucleosome. Curr Opin Genet Dev. 1998; 8(2):140-6. DOI: 10.1016/s0959-437x(98)80134-2. View

16.

Mancuso M, Orsucci D, Choub A, Siciliano G . Current and emerging treatment options in the management of Friedreich ataxia. Neuropsychiatr Dis Treat. 2010; 6:491-9. PMC: 2938298. DOI: 10.2147/ndt.s6916. View

17.

Mackenzie I, Ansorge O, Strong M, Bilbao J, Zinman L, Ang L . Pathological heterogeneity in amyotrophic lateral sclerosis with FUS mutations: two distinct patterns correlating with disease severity and mutation. Acta Neuropathol. 2011; 122(1):87-98. PMC: 3319073. DOI: 10.1007/s00401-011-0838-7. View

18.

Al-Chalabi A, Jones A, Troakes C, King A, Al-Sarraj S, van den Berg L . The genetics and neuropathology of amyotrophic lateral sclerosis. Acta Neuropathol. 2012; 124(3):339-52. DOI: 10.1007/s00401-012-1022-4. View

19.

Rademakers R, Cruts M, Van Broeckhoven C . The role of tau (MAPT) in frontotemporal dementia and related tauopathies. Hum Mutat. 2004; 24(4):277-95. DOI: 10.1002/humu.20086. View

20.

Greer E, Shi Y . Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet. 2012; 13(5):343-57. PMC: 4073795. DOI: 10.1038/nrg3173. View